


Healthcare News Roundup: Ophthalmology
HSMN NewsFeed - 18 May 2021
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
HSMN NewsFeed - 7 Apr 2021
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device
